Bio tech company updates — 8/8/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Recent coverage highlights two developments involving South Korean biotechnology companies: L&C Bio is preparing an injectable intended to restore facial volume after significant weight loss, while Korean pharmaceutical groups are reviewing underperforming M&A subsidiaries through capital support and leadership changes.
Key Findings
- L&C Bio is preparing a facial-volume injectable. BusinessToday reports that the South Korean biotech company is developing an injectable made from donated human fat for people experiencing facial-volume loss after substantial weight loss.
- The company says its technology was developed approximately five years ago. L&C Bio CEO Lee Whan Chul said the technology is patented in South Korea, the United States and China.
- Korean pharma companies are addressing losses at acquired subsidiaries. Seoul Economic Daily reports that companies including SD Biosensor and LG Chem are injecting additional capital and replacing subsidiary CEOs in efforts to restore profitability.
Details
L&C Bio targets post-weight-loss facial-volume loss
L&C Bio is preparing an injectable treatment designed to restore facial volume lost after significant weight reduction. The product is made from donated human fat, according to BusinessToday.
The company’s chief executive, Lee Whan Chul, said the underlying technology was developed around five years ago and is protected by patents in South Korea, the United States and China.
The report links the product opportunity to concerns about facial-volume loss associated with major weight reduction, including weight loss connected with medicines commonly discussed under the “Ozempic face” label.
M&A subsidiaries remain a profitability challenge
Korean pharmaceutical companies are taking corrective measures at subsidiaries acquired through mergers and acquisitions. Seoul Economic Daily reports that SD Biosensor and LG Chem are among the companies dealing with losses at M&A subsidiaries.
The reported responses include providing fresh capital and changing subsidiary leadership, with the stated objective of restoring profitability.
The developments point to continued pressure on Korean biopharma groups to improve the performance of acquired businesses rather than relying only on acquisition-driven expansion. This is an analytical interpretation of the measures reported by Seoul Economic Daily.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
